232 related articles for article (PubMed ID: 37959874)
1. New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study.
Fakhry MM; Mattar AA; Alsulaimany M; Al-Olayan EM; Al-Rashood ST; Abdel-Aziz HA
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959874
[No Abstract] [Full Text] [Related]
2. Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.
Sever B; Altıntop MD; Radwan MO; Özdemir A; Otsuka M; Fujita M; Ciftci HI
Eur J Med Chem; 2019 Nov; 182():111648. PubMed ID: 31493743
[TBL] [Abstract][Full Text] [Related]
3. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
[TBL] [Abstract][Full Text] [Related]
4. New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity.
Sabry MA; Ghaly MA; Maarouf AR; El-Subbagh HI
Eur J Med Chem; 2022 Nov; 241():114661. PubMed ID: 35964425
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with
Abdelsalam EA; Abd El-Hafeez AA; Eldehna WM; El Hassab MA; Marzouk HMM; Elaasser MM; Abou Taleb NA; Amin KM; Abdel-Aziz HA; Ghosh P; Hammad SF
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2265-2282. PubMed ID: 36000167
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, biological assessment and molecular modeling studies of novel imidazothiazole-thiazolidinone hybrids as potential anticancer and anti-inflammatory agents.
Kamboj P; Anjali ; Imtiyaz K; Rizvi MA; Nath V; Kumar V; Husain A; Amir M
Sci Rep; 2024 Apr; 14(1):8457. PubMed ID: 38605072
[TBL] [Abstract][Full Text] [Related]
7. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors.
Farouk AKBAW; Abdelrasheed Allam H; Rashwan E; George RF; Abbas SE
Bioorg Chem; 2022 Nov; 128():106099. PubMed ID: 35994884
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L
Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and anti-proliferative activity of some new quinoline based 4,5-dihydropyrazoles and their thiazole hybrids as EGFR inhibitors.
George RF; Samir EM; Abdelhamed MN; Abdel-Aziz HA; Abbas SE
Bioorg Chem; 2019 Mar; 83():186-197. PubMed ID: 30380447
[TBL] [Abstract][Full Text] [Related]
11. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
12. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives.
Alkamaly OM; Altwaijry N; Sabour R; Harras MF
Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000351. PubMed ID: 33252142
[TBL] [Abstract][Full Text] [Related]
13. New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation.
Warda ET; Shehata IA; El-Ashmawy MB; El-Gohary NS
Bioorg Med Chem; 2020 Nov; 28(21):115674. PubMed ID: 33065442
[TBL] [Abstract][Full Text] [Related]
14. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, molecular docking and biological activity evaluation of some novel indole derivatives as potent anticancer active agents and apoptosis inducers.
El-Sharief AMS; Ammar YA; Belal A; El-Sharief MAMS; Mohamed YA; Mehany ABM; Elhag Ali GAM; Ragab A
Bioorg Chem; 2019 Apr; 85():399-412. PubMed ID: 30665034
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2.
Alkahtani HM; Abdalla AN; Obaidullah AJ; Alanazi MM; Almehizia AA; Alanazi MG; Ahmed AY; Alwassil OI; Darwish HW; Abdel-Aziz AA; El-Azab AS
Bioorg Chem; 2020 Jan; 95():103461. PubMed ID: 31838290
[TBL] [Abstract][Full Text] [Related]
19. New 2-alkoxycyanopyridine derivatives as inhibitors of EGFR, HER2, and DHFR: Synthesis, anticancer evaluation, and molecular modeling studies.
Hawas SS; El-Sayed SM; Elzahhar PA; Moustafa MA
Bioorg Chem; 2023 Dec; 141():106874. PubMed ID: 37769524
[TBL] [Abstract][Full Text] [Related]
20. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]